SB 1528
Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.
Jurisdiction
Oregon
Session
2026 Regular Session
At the request of
(at the request of Senate Interim Committee on Health Care)
Committee
Rules
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take actionPublic sentiment
Support
29%
Oppose
71%
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Bill overview
This bill requires drug manufacturers to provide more detailed reports to the Oregon Health Authority (OHA) about their operations. Specifically, it expands reporting requirements to include all patient assistance programs offered or funded by the manufacturer for consumers in Oregon. The bill also mandates reporting on factors contributing to price increases, research and development costs, and sales revenue for prescription drugs. OHA will use this information to verify manufacturer reports and provide recommendations to the legislature regarding prescription drug costs.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Senate Interim Committee on Health Care
Arguments in favor
Reasons to support this legislation.
Supporters of Senate Bill 1528 generally agree that the proposed amendment is crucial for improving transparency in Oregon's healthcare system, particularly with regards to patient assistance programs. By requiring annual reporting from manufacturers on their funded or maintained programs, proponents argue that this will provide a more complete picture of how these programs influence drug affordability and enable data-driven decision making. They believe that increased transparency will lead to cost management, improved patient care, and smarter policymaking to make prescription drugs more affordable for Oregonians, ultimately addressing the state's rising healthcare costs and ensuring that consumers have access to necessary medications without financial burden.
Source: Testimony Summaries
Arguments opposed
Reasons to oppose this legislation.
Opponents of SB 1528-2 express widespread concern that the legislation infringes on individual autonomy, bodily integrity, and freedom from government overreach. They argue that the bill's requirements for reporting confidential data to the Oregon Health Authority would compromise patient privacy and manufacturers' proprietary information, while also failing to address existing barriers to accessing affordable medications. Many that the measure would concentrate excessive authority in one agency, potentially leading to unwarranted directives and a lack of transparency in decision-making processes. Additionally, opponents argue that the bill's vagueness and potential for regulatory burden without clear benefits would lead to inefficiencies in healthcare delivery and undermine patient autonomy in medical decisions.
Read the latest version inline or switch to a previous version.